Filing Details
- Accession Number:
- 0000950170-24-011394
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-05 18:07:48
- Reporting Period:
- 2024-02-01
- Accepted Time:
- 2024-02-05 18:07:48
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1567514 | Intra-Cellular Therapies Inc. | ITCI | Pharmaceutical Preparations (2834) | 364742850 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1756211 | Mark Neumann | C/O Intra-Cellular Therapies, Inc. 430 East 29Th Street New York NY 10016 | Evp, Chief Commercial Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-02-01 | 11,860 | $0.00 | 41,560 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2024-02-02 | 4,956 | $66.67 | 36,604 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-02-02 | 6,904 | $67.49 | 29,700 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Represents shares issued upon the vesting of performance stock units.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023. A majority of the proceeds from this sale will be used tocover the reporting person's tax liability arising from the vesting of performance stock units.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.1 to $67.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.16 to $68.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Billionaire Hedge Funds
